Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus STREPTOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus STREPTOMYCIN SULFATE.
GENOSYL vs STREPTOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by causing misreading of mRNA and preventing initiation complex formation.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
Intramuscular: 15 mg/kg/day (max 1 g/day) divided every 12 hours; intraperitoneal: 1 g/dialysis cycle; intrathecal: 1 mg/kg/day.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Terminal elimination half-life is 2-3 hours in patients with normal renal function. In anuria or severe renal impairment, half-life may extend to 50-100 hours. Neonates have a prolonged half-life of 5-10 hours due to immature renal function.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Primarily renal excretion via glomerular filtration; 80-98% of the dose is excreted unchanged in urine within 24 hours. Minor biliary excretion (less than 1%). Fecal excretion is negligible.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic